Athersys Announces Upcoming Presentations at the International Society of Cell and Gene Therapy Virtual Conference
May 18 2020 - 6:00AM
Business Wire
Company will participate in three events at
the largest global translation-focused cell and gene therapy
meeting
Athersys, Inc. (NASDAQ: ATHX) announced today its participation
in several sessions at this year’s International Society for Cell
and Gene Therapy (ISCT) virtual conference taking place May 28 –
29, 2020. ISCT 2020 is the largest global translation-focused cell
and gene therapy (CGT) meeting and is expected to draw delegates
from more than 50 countries in the virtual event. Dr. Anthony Ting,
Vice President of Regenerative Medicine and Head of Cardiopulmonary
Programs and co-chair for the Strategies for Commercialization
track at the ISCT 2020 virtual conference, will take an active role
in three separate events.
Dr. Ting pre-recorded a talk titled “MultiStem® for Acute
Respiratory Distress Syndrome (MUST-ARDS study)” for the “State of
the Art: Success and Failure of Cell Therapy Clinical Trials for
Acute and Chronic Lung Diseases” session, which will be available
for on-demand listening for all registered participants. Dr. Ting
presented the data from the Company’s completed Phase 1/2 acute
respiratory distress (ARDS) study.
Dr. Ting will also serve as the chair for the live session
titled “Strategies for Commercialization Plenary Session - Is Big
Pharma Ready for Industrial Scale Cell and Gene Therapy?” taking
place on May 29 at 8:00 AM PDT, in addition to speaking at the live
session titled “ISCT CSO Global Showcase on COVID-19, Part II - A
New Hope” on May 29 at 4:00 PM PDT. Dr. Ting will speak on the
topic of Industry-led Cell Therapy Clinical Trials for COVID-19
that will include the Company’s recently initiated MACOVIA
(MultiStem® Administration for COVID-19 Induced Acute
Respiratory Distress Syndrome) trial.
All sessions are only available to those that have registered
for the ISCT Conference. Non-members who register will include a
complimentary 2020 ISCT E-Membership. ISCT 2020 Paris Virtual will
be accessible remotely and on-demand, including live and recorded,
in addition to networking events, poster halls, and 1-on-1
partnering opportunities. A peer curated scientific program
addressing timely and critical topics across the full cell and gene
therapy development and translation spectrum, including 35 sessions
with over 50 hours of both live and on demand streaming, and access
to a global line-up of leading experts in CGT and six live
broadcasted Plenary Sessions will focus on the latest translation
advancements from basic research, pre-clinical studies and clinical
trials for a variety of therapeutic modalities.
For more information and to register, please visit
www.ISCT2020.com.
About the International Society for Cell & Gene
Therapy
Established in 1992, the International Society for Cell &
Gene Therapy (ISCT) is a global society of clinicians, regulators,
researchers, technologists and industry partners with a shared
vision to translate cellular and gene therapy into safe and
effective therapies to improve patients’ lives worldwide.
ISCT is the global leader focused on pre-clinical and
translational aspects of developing cell and gene-based
therapeutics, thereby advancing scientific research into innovative
treatments for patients. ISCT offers a unique collaborative
environment that addresses three key areas of translation:
Academia, Regulatory and Commercialization. Through strong
relationships with global regulatory agencies, academic
institutions and industry partners, ISCT drives the advancement of
research into standard of care.
Comprised of over 1800 cell and gene therapy experts across five
geographic regions and representation from over 60 countries, ISCT
members are part of a global community of peers, thought leaders
and organizations invested in cell and gene therapy translation.
For more information about the society, key initiatives and
upcoming meetings, please visit: www.isctglobal.org /
@ISCTglobal.
About Athersys
Athersys is an international biotechnology company engaged in
the discovery and development of therapeutic product candidates
designed to extend and enhance the quality of human life. The
Company is developing its MultiStem® cell therapy product, a
patented, adult-derived “off-the-shelf” stem cell product,
initially for disease indications in the neurological, inflammatory
and immune, cardiovascular, and other critical care indications and
has several ongoing clinical trials evaluating this potential
regenerative medicine product. Athersys has forged strategic
partnerships and a broad network of collaborations to further
advance the MultiStem cell therapy toward commercialization. More
information is available at www.athersys.com. Follow Athersys on
Twitter at www.twitter.com/athersys.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200518005076/en/
Ivor Macleod Chief Financial Officer Tel: (216) 431-9900
ir@athersys.com
Karen Hunady Director of Corporate Communications & Investor
Relations Tel: (216) 431-9900 khunady@athersys.com
David Schull Russo Partners, LLC Tel: (212) 845-4271 or (858)
717-2310 David.schull@russopartnersllc.com
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Athersys (NASDAQ:ATHX)
Historical Stock Chart
From Apr 2023 to Apr 2024